Momelotinib treatment reduced BMP signaling-induced expression of PNPLA3 and alleviated the PNPLA3 I148M-mediated triglyceride accumulation in MASH model.429. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatohepatitis.